Loading stock data…
SAN.PA
€73.22+0.12 (+0.16%)
Market ClosedLast close May 11
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sanofi in the Healthcare sector is trading at €73.22. The stock is currently near its 52-week low of €72.74, remaining 5.9% below its 200-day moving average. Technical signals show neutral RSI of 30 and bearish MACD signal, explaining why SAN.PA maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 30) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price€73.22
Potential Downside
3.6%
Whystock Fair Value€70.61
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus23 analysts
Buy
Mean target€97.10+32.6%
Range€82.00 – €112.00
Fundamentals
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
€97.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.04
Beta
Defensive asset. Lower volatility than the S&P 500.
0.32
Div Yield
Strong income play. Yield provides a meaningful total return floor.
510.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.65%
Volume
Today's trading volume
2.32M
Recent News
Sanofi Leans On AI And Rare Disease Detection To Shape Future Returns
Sanofi expanded its global AI Centre of Excellence in Toronto to support research, development, and manufacturing of medicines and vaccines using advanced artificial intelligence. The company also sponsored AlphaDetect, a collaboration focused on improving routine detection of Alpha-1 Antitrypsin Deficiency, a rare genetic condition. These moves highlight continued investment in digital tools and rare disease detection as part of Sanofi's broader focus on patient care. For investors...
Health Care Roundup: Market Talk
Find insight on Amazon Pharmacy, Sanofi, Sunway Health and more in the latest Market Talks covering the health care sector.
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.
Novavax, Inc. Q1 2026 Earnings Call Summary
Moby summary of Novavax, Inc.'s Q1 2026 earnings call
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.